Therapeutic potential of interferon-γ and its antagonists in autoinflammation: Lessons from murine models of systemic juvenile idiopathic arthritis and macrophage activation syndrome by Avau, Anneleen & Matthys, Patrick
 Pharmaceuticals 2015, 8, 793-815; doi:10.3390/ph8040793 
 
pharmaceuticals 
ISSN 1424-8247 
www.mdpi.com/journal/pharmaceuticals 
Review 
Therapeutic Potential of Interferon-γ and Its Antagonists in 
Autoinflammation: Lessons from Murine Models of  
Systemic Juvenile Idiopathic Arthritis and Macrophage 
Activation Syndrome 
Anneleen Avau and Patrick Matthys * 
Laboratory of Immunobiology, Department of Microbiology and Immunology, Rega Institute,  
KU Leuven - University of Leuven, Leuven B-3000, Belgium; E-Mail: anneleen.avau@rega.kuleuven.be 
* Author to whom correspondence should be addressed; E-Mail: patrick.matthys@rega.kuleuven.be; 
Tel.: +32-1633-7349; Fax: +32-1633-7340. 
Academic Editor: Howard A. Young 
Received: 16 October 2015 / Accepted: 18 November 2015 / Published: 25 November 2015 
 
Abstract: Interferon-γ (IFN-γ) affects immune responses in a complex fashion.  
Its immunostimulatory actions, such as macrophage activation and induction of T helper  
1-type responsiveness, are widely acknowledged, however, as documented by a large body 
of literature, IFN-γ has also the potential to temper inflammatory processes via other pathways. 
In autoimmune and autoinflammatory disorders, IFN-γ can either play a disease-enforcing 
role or act as protective agent, depending on the nature of the disease. In animal models of 
any particular autoimmune disease, certain changes in the induction procedure can reverse 
the net outcome of introduction or ablation of IFN-γ. Here, we review the role of endogenous 
IFN-γ in inflammatory disorders and related murine models, with a focus on systemic 
juvenile idiopathic arthritis (sJIA) and macrophage activation syndrome (MAS). In particular, 
we discuss our recent findings in a mouse model of sJIA, in which endogenous IFN-γ  
acts as a regulatory agent, and compare with results from mouse models of MAS. Also,  
we elaborate on the complexity in the activity of IFN-γ and the resulting difficulty of 
predicting its value or that of its antagonists as treatment option. 
Keywords: interferon-γ; therapy; autoinflammation; systemic juvenile idiopathic arthritis; 
mouse model 
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1. Introduction 
The family of interferons (IFNs) represents cytokines with viral “interference” properties. Three groups 
of IFNs have been described, based on their respective receptors. The type I IFN family is the largest, 
with IFN-α and IFN-β as archetypal members. All type I IFNs are related by structure and bind to a 
common heterodimeric receptor (IFNAR) [1]. The recently defined third subgroup of IFNs, consisting 
of IFN-λ subtypes, exerts actions similar to those of type I IFNs, but uses a different cell surface receptor 
(IFNLR). Interferon-γ (IFN-γ), discovered in the early 1960s, is the sole type II IFN. While IFN-γ owes 
its name and classification as an IFN to its antiviral activity [2], it differs from other IFNs in many  
ways [3]. Indeed, IFN-γ is encoded by a separate chromosomal locus, has its own receptor (IFNGR) and 
differs structurally from other types [4]. While both type I and type III IFNs are essential for antiviral 
immunity, the antiviral properties of IFN-γ represent only a subordinate part of its immunomodulatory 
functions. As deducted from studies in mice and individuals with errors in the IFN-γ pathways, a unique 
function of IFN-γ consists of defense against intracellular bacteria, fungi and parasites [5]. In contrast to 
type I IFNs, which are produced by virus-infected cells, IFN-γ is a product of immune cells in response 
to various stimuli. Predominant sources are natural killer (NK) cells and activated T cells, but B cells, 
NKT cells and antigen-presenting cells have also been described. Production and secretion of IFN-γ are 
under positive regulatory control by interleukin (IL)-12 and IL-18, cytokines that themselves are derived 
from antigen-presenting cells. IFN-γ orchestrates its many cellular reactions through induction of gene 
transcription via the Janus kinase (JAK)/signal transducer and activator of transcription  
(STAT)-pathway [4]. The role of IFN-γ in a certain disorder can be proinflammatory or regulatory, which 
explains the difficulty to predict its value (or that of its antagonists) as a treatment option. 
2. Pro- and Anti-Inflammatory Aspects of Interferon-γ 
IFN-γ both promotes proinflammatory pathways, like host defense against intracellular pathogens, 
and exerts regulatory functions, such as induction of T cell apoptosis. The net effect of IFN-γ signaling 
depends on the context and time frame wherein the disease progresses [6–8]. Table 1 provides an 
overview of prominent immune-stimulatory and anti-inflammatory effects of IFN-γ. 
Table 1. General properties of interferon-γ in immune pathways. 
Proinflammatory Anti-Inflammatory 
Macrophage activation Inhibition of Th2 and Th17 polarization 
Upregulation of antigen presentation pathways Induction of IDO 
NK cell activation Induction of T cell apoptosis 
Induction of Th1 polarization Inhibition of neutrophil specific chemokines 
Stimulation of monocyte chemoattractants Inhibition of tissue damage  
Upregulation of cell adhesion molecules Inhibition of osteoclastogenesis 
B cell maturation Induction of IL-18 binding protein  
Abbreviations: IDO, indoleamine 2,3-dioxygenase; NK, natural killer; Th, T helper. 
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2.1. Macrophage Activation and Enhancement of Immune Pathways 
IFN-γ favors innate immune inflammatory responses through specific pathways in macrophage 
activation. These pathways include direct effects through the induction of effector gene transcription, 
and indirect effects through the enhancement of macrophage responsiveness to inflammatory stimuli [9]. 
Thus, IFN-γ induces the expression of MHC I and II antigens, the IL-2 receptor, complement receptors 
and several cytokines in a direct way. It enhances cytotoxicity of macrophages against tumor cells and 
infectious agents through induction of reactive oxygen and nitrogen species [3]. Indirectly, IFN-γ 
augments the sensitivity of macrophages to inflammatory triggers by increasing the expression of  
Toll-like receptors (TLRs) and inducing transcription factors that are essential for expression of  
TLR-responsive genes. As a result, the TLR-induced expression of inflammatory mediators and immune 
effectors, e.g., cytokines and chemokines, is augmented after IFN-γ priming [9,10]. As already indicated, 
IFN-γ promotes antigen presentation through upregulation of MHC molecules, entailing the increased 
expression of many different genes which all contribute to the antigen presentation pathways. IFN-γ is 
particularly specialized in the regulation of class II expression by antigen-presenting cells [11]. By this 
mechanism, it provides a link between innate and adaptive immunity. With respect to MHC I antigen 
presentation, IFN-γ plays an important role in the formation of the immunoproteasome. Thus, IFN-γ 
induces replacement of the three catalytically active β subunits of the proteasome into inducible catalytic 
subunits that ensure optimal quality and quantity of the generated peptides for presentation on MHC 
class I molecules [12]. 
NK cells are important sources of IFN-γ, particularly when stimulated with IL-12 and IL-18 [13,14]. 
In addition, IFN-γ is an enhancer of cytotoxic NK cell activity [15–18]. Accordingly, NK cells are 
defective in IFN-γ-deficient mice [19,20]. Of note, IFN-γ is the most potent inducer of IL-18 binding 
protein, a significant inhibitor of IL-18 [21]. By this regulatory function, IFN-γ induces a negative 
feedback pathway in inflammatory processes, also affecting its own production by NK cells. In B cells, 
IFN-γ acts directly on the secretion of antibodies by regulating the Ig class switching from IgM to a 
downstream isotype [11]. 
2.2. Modulation of T Helper and Regulatory T Cell Responses 
T helper (Th) cells are central players in the IFN-γ network cascades. They serve as important sources 
of IFN-γ, and their development is profoundly affected by the cytokine. Th cells are categorized 
depending on a set of polarizing cytokines, a particular cytokine production profile and relatively unique 
master gene regulators. Although commitment of Th cell lineages was originally seen as a unidirectional 
process of terminal differentiation, recent findings indicate that these processes are plastic and reversible, 
with important implications for autoimmune and autoinflammatory diseases [22]. IFN-γ and IL-2 are 
characteristic cytokine products of the Th1 population, while IL-4 is a marker of the Th2 lineage (Figure 1). 
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Figure 1. Polarization of T helper cell subsets and regulatory T cells. Naïve T cells (left) 
differentiate into different T helper (Th) lineages (Th1, Th2, and Th17) and regulatory T 
(Treg) cells. This polarization is stimulated or counteracted by different cytokine signals 
(indicated respectively by blue arrows and red lines). IL-12 and IFN-γ stimulate the 
development of Th1 cells, with T-Bet as master transcription factor. Th1 cells mainly 
produce IFN-γ and IL-2. IL-4 and IL-6 induce Th2 polarization. Th2 cells have Gata3 as 
major gene regulator, and predominantly produce IL-4, IL-5 and IL-13. TGF-β induces Th17 
polarization when combined with IL-6, while IL-23 is required for Th17 differentiation. 
Signature products of Th17 cells are IL-17 and IL-22, while their master gene regulator is 
RORγt. In the absence of IL-6 or IL-23, TGF-β induces Treg cell formation, with FoxP3 as 
major transcription factor and IL-10 and TGF-β as major products. IFN-γ inhibits Th2 and 
Th17 cell polarization and stimulates Treg cell development under specific inflammatory 
conditions, while IL-4 suppresses Th1 and Th17 differentiation. 
Differentiation towards Th1 cells is mainly induced by IL-12, but IFN-γ accelerates and enhances 
these effects. IL-4 and IL-6 are important inducers of Th2 cell formation. Thus, both IFN-γ and IL-4 
auto-amplify responses of their producer T cell subgroup. Furthermore, IFN-γ and IL-4 are potent 
antagonists, cross-inhibiting differentiation and function of Th2 and Th1 cells [10,11]. In the early 2000s, 
an additional Th cell subgroup, the so-called Th17 population, was identified by the production of  
IL-17 [23]. Th17 cells were shown to be important for host defense against extracellular bacteria and 
yeasts, by promoting granulopoiesis, neutrophil infiltration and neutrophil activation. The Th17 subset 
is very heterogeneous and plastic. In contrast to Th1 and Th2 cells, which are induced by their own 
products, polarization of naïve T cells towards Th17 cells is not mediated by IL-17. IL-6 in combination 
with low concentrations of transforming growth factor (TGF)-β cooperate to induce Th17 cell 
differentiation, while IL-23 is needed downstream to stimulate proliferation and cytokine production [22,24]. 
Both IFN-γ and IL-4 inhibit polarization towards Th17 cells [24]. However, the relationship between 
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Th17 and Th1 cells and between their signature products IL-17 and IFN-γ as opponents is complicated 
by the observation of IL-17/IFN-γ double-positive cells [25,26]. Elevated amounts of these cells can be 
detected in chronic inflammatory disorders, although their exact role in disease pathogenesis remains 
unclear. Finally, another T cell lineage, the regulatory T (Treg) cell subset, exerts important  
anti-inflammatory functions, e.g., restraining effector T cells, suppressing Th1, Th2 and Th17 cells, 
producing the anti-inflammatory IL-10 and maintaining homeostasis. Their development is induced by 
high concentrations of TGF-β, in the absence of proinflammatory cytokines such as IL-6 and IL-23. In 
certain inflammatory contexts, like experimental autoimmune encephalomyelitis (EAE) and  
collagen-induced arthritis (CIA), models for multiple sclerosis (MS) and rheumatoid arthritis (RA) 
respectively, IFN-γ favors regulatory over effector differentiation by stimulating Treg cell expansion [7]. 
As a consequence, it suppresses the formation of Th1 cells in an indirect negative feedback loop [10,22]. 
However, development of Treg cells proceeds normally in the absence of IFN-γ under several  
conditions [27]. Of note, IFN-γ indirectly promotes Treg development through the induction of 
indoleamine 2,3-dioxygenase (IDO), an immunomodulatory enzyme which catalyzes the degradation of 
tryptophan to kynurenine [28,29]. Furthermore, Koch et al. demonstrated that IFN-γ induced the 
expression of T-bet in FoxP3+ cells, representing a novel subset of Treg cells that dampens Th1 cell 
responses [30]. 
The mechanism by which IFN-γ regulates T cell immune circuits is not restricted to the modulation 
of Th cell commitment. Indeed, IFN-γ was demonstrated to be essential for the termination of immune 
responses by inducing apoptotic cell death in the T cell compartment in conditions of chronic 
inflammation with prolonged antigen stimulation and responses to self-antigens [31,32]. 
2.3. Influence on Chemokine Production and Attenuation of Tissue Destruction 
Chemokines are produced by a variety of cells so as to attract specific immune cells. IFN-γ upregulates 
the expression of several chemokines, such as IFN-inducible protein (IP)-10 and monocyte chemoattractant 
protein (MCP)-1, as well as adhesion molecules, including intercellular adhesion molecule (ICAM)-1 
and vascular cell adhesion molecule (VCAM)-1. These molecules specifically orchestrate the attraction 
of mononuclear cells to the inflammation spot [4]. Conversely, neutrophil attracting chemokine 
production is generally inhibited by IFN-γ [8]. 
Acute as well as chronic immune reactions cause collateral damage to the host, certainly when these 
reactions are not restrained in an appropriate way. IFN-γ precisely regulates the balance between 
clearance of pathogens and attenuation of inflammation-associated tissue damage. IFN-γ confines tissue 
damage by inhibiting the production of tissue-destructive factors, including matrix metalloproteinases, 
serine proteases and complement components [10]. Furthermore, tissue infiltration of neutrophils and 
monocytes is repressed by IFN-γ via several mechanisms: first, myelopoiesis and granulopoiesis are 
attenuated; secondly, neutrophil-attracting chemokine production is inhibited; and thirdly, cellular 
responsiveness to chemokines is altered by IFN-γ. Also, IFN-γ reduces damage in bone tissue as it 
suppresses formation of osteoclasts [7,8,10]. 
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2.4. Recombinant IFN-γ as Therapy in Mycobacterial Infections 
As indicated above, IFN-γ is indispensable in the immune defense against intracellular pathogens. 
Patients and mice with mutations in IFN-γ pathway genes are extremely susceptible for mycobacterial 
disease [5]. Therefore, recombinant IFN-γ is a conceivable treatment option for tuberculosis. Although 
previous clinical trials showed only moderate results, more studies are now conducted in different patient 
subgroups and with other routes of administration. Indeed, the results strongly depend on a combination 
of factors, including the dose, route and timing of drug administration, the immune status of the host and 
the type of infection [33]. 
3. Interferon-γ in Autoinflammation: Focus on Systemic Juvenile Idiopathic Arthritis 
Autoinflammatory syndromes are characterized by episodes of seemingly unprovoked recurrent 
inflammatory attacks of an innate immune nature. In contrast to the traditionally defined autoimmune 
disorders, autoinflammatory diseases lack high-titer auto-antibodies or autoreactive T cells [34]. Systemic 
juvenile idiopathic arthritis (sJIA) is an example of such a disease, in which excessive activation of 
innate immune pathways dominates the inflammatory responses. A cytokine storm plays a signature role 
in the syndrome, as symptoms can be explained by the high levels of proinflammatory cytokines such 
as IL-6 and IL-18. Controversy exists, however, on the role of IFN-γ in sJIA [35]. In this section, we 
provide an overview of the pathogenesis of sJIA and its complication macrophage activation syndrome 
(MAS). We further elaborate on a recently developed CFA-induced mouse model of sJIA in which a 
protective role was assigned to IFN-γ and compare the model with findings from other CFA-induced 
experimental models as well as mouse models of MAS. 
3.1. Pathogenesis of Systemic Juvenile Idiopathic Arthritis and Current Treatment Recommendations 
Systemic juvenile idiopathic arthritis (sJIA), originally described by George Frederic Still in 1897 [36] 
and formerly known as systemic juvenile rheumatoid arthritis, systemic juvenile chronic arthritis, or 
Still’s disease, is a perplexing childhood disorder. The disease is classified as a subtype of juvenile 
idiopathic arthritis (JIA), a heterogeneous group of diseases defined by persistent arthritis of unknown 
origin that starts before the age of 16 and continues for at least 6 weeks [37]. JIA is the most common 
chronic rheumatic syndrome in childhood, with an incidence and prevalence that approximate to 10 and 
100 cases per 100,000 children, respectively [38–40]. Based on the number of joints involved and the 
presence of extra-articular symptoms, the International League of Associations for Rheumatology 
(ILAR) classified JIA into seven different, mutually exclusive categories, of which oligoarticular  
and polyarticular JIA are the most common [37,38]. sJIA constitutes ~10% of all cases of JIA seen in 
North America and Europe, with a yearly incidence of ~0.8 cases per 100,000 children. Although sJIA 
can present at any time during childhood, a broad peak in the age of presentation was observed  
between 0 and 5 years, with 2 years of age most commonly reported [41]. Both sexes are equally  
affected [37,39,40]. Although classified as a subtype of JIA, symptoms are specific and different from 
those of other forms of childhood arthritis. According to the definition set by the ILAR [37], sJIA is 
characterized by arthritis in one or more joints, together with quotidian fever for at least 2 weeks, and 
accompanied by evanescent erythematous rash, generalized lymph node enlargement, hepatomegaly, 
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splenomegaly and/or serositis. Exclusions from the sJIA diagnosis are made when other characteristic 
symptoms, like psoriasis or enthesitis, are encountered [37]. sJIA knows a highly variable presentation 
and course, with arthritis sometimes not developing until weeks to months after the first systemic signs. 
In general, systemic symptoms overshadow arthritis; the patients feel very ill and frequently develop 
weight loss [35,42,43]. It is therefore difficult to correctly diagnose sJIA: symptoms overlap with other 
conditions and the presentation differs substantially between patients. Although no specific laboratory 
tests exist for sJIA, the majority of patients has a typical pattern of systemic inflammatory markers. 
Characteristic abnormalities are high levels of C-reactive protein (CRP), high erythrocyte sedimentation 
rates (ESR), neutrophilia, thrombocytosis, and hypochromic normo- or microcytic anemia [42,43]. 
Autoantibodies are uncommon, but raised levels of polyclonal immunoglobins are repeatedly 
demonstrated. Elevated levels of ferritin and D-dimers are often seen, together with high levels of 
proinflammatory cytokines and chemokines [42,43]. Table 2 provides a detailed overview of generally 
described symptoms of sJIA. 
The etiology of sJIA is largely unknown. Although infections are suspected as triggers, the absence 
of consistent seasonality and the low frequency in family members indicate that an infection is just one 
possible trigger among many others. One thought is that sJIA is initiated in children with a genetic 
susceptibility by infectious agents that are normally encountered during childhood. Once initiated, genetic 
polymorphisms contribute to the excessive reaction of the immune system. Associations with many genes 
have been described, supporting the idea that sJIA is multigenic and that different alleles are involved in 
the genetic predisposition [35,42–44]. In a first genomewide association study of sJIA, inherited risk 
factors were found within the class II human leukocyte antigen (HLA) locus [45,46]. Also, polymorphisms 
in non-HLA genes, e.g., in the promoter and genes encoding tumor necrosis factor (TNF)-α, the IL-1 
family, IL-6 or IL-10, have repeatedly been described to be associated with sJIA [47–51]. Together, the 
associated polymorphisms in genes related to both innate and adaptive immunity demonstrate that sJIA 
is a complex disorder, suggesting contribution of both autoimmunity and autoinflammation. Of note, the 
presence of autoantibodies, autoreactive T cells or autoantigens has so far not been reported. 
Though accounting for only 10% of the overall JIA prevalence, sJIA is responsible for most of the 
mortality seen in the disease group. An important cause of the high morbidity and mortality is its 
association with MAS, a life-threatening complication of several chronic childhood diseases which was 
first described in 1983 in association with sJIA [35,52]. MAS is characterized by excessive activation 
and/or expansion of T cells and macrophages, resulting in an overwhelming systemic inflammatory 
reaction and cytokine storm [53]. The overall clinical presentation of MAS includes an acute illness with 
unremitting high fever, hepatosplenomegaly, lymphadenopathy and mental status changes. Due to 
abnormalities in the coagulation profile, patients may have mucosal bleedings and purpura, resembling 
disseminated intravascular coagulopathy. Hallmark laboratory abnormalities are decreased blood cell 
numbers, i.e., leukopenia, thrombocytopenia and anemia, highly elevated ferritin levels and elevated 
serum liver enzymes. A sudden fall in ESR despite persistently high CRP is also a distinctive  
feature. Triglycerides and lactate dehydrogenase levels are usually elevated, while sodium levels are 
depressed [53–55]. Symptoms of MAS overlap substantially with those of sJIA, making the recognition 
challenging. Several features, like lymphadenopathy and organomegaly, are common between the 
disorders. Other symptoms of MAS may be masked at first by the underlying sJIA symptoms.  
For example, blood values like platelet and neutrophil counts are increased during active sJIA, and may 
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initially return to apparent normal levels during an MAS episode. As a result, changes only become 
evident at the late stage of the syndrome [53]. Table 2 provides an overview of MAS symptoms in a 
sJIA background. A pathognomonic feature of MAS is the appearance of hemophagocytic macrophages, 
i.e., well-differentiated macrophages that engulf cells of hematopoietic origin [53]. Whether these 
macrophages are cause or consequence of the symptoms, and whether they exert a proinflammatory or 
rather a protective role in the disease, is still subject of investigations, but they serve as diagnostic 
markers [56]. The finding of prominent hemophagocytic activity by overactivated macrophages in 
patient bone marrow aspirates led to the term “macrophage activation syndrome” [57]. It is now widely 
acknowledged that the disease is a subtype of the hemophagocytic lymphohistiocytosis (HLH) 
syndromes [58], in which hemophagocytic macrophages are commonly demonstrated [59]. Due to the 
overlap in symptoms, sJIA and MAS are sometimes seen as the same entity within a spectrum  
of severity, with clinically unapparent MAS at one end and fulminant MAS at the other [58,60].  
The demonstration of subclinical MAS symptoms, i.e., hemophagocytosis in bone marrow aspirates of 
more than 50% of sJIA patients [61], certainly points in that direction. 
Table 2. Symptoms of sJIA and MAS in association with sJIA [35,37,39,41,42,53,54,62–67]. 
 Feature sJIA MAS 
 Incidence ~1/100,000 
~10% of sJIA 
patients 
Clinical Features 
Fever Quotidian Persistent 
Rash Evanescent Petechial/macular 
Hepatomegaly + + 
Splenomegaly + + 
Lymphadenopathy + + 
Arthritis + - 
Serositis + - 
CNS dysfunction −/+ + 
Laboratory 
Characteristics 
Neutrophil count ↑↑ ↓ 
Platelet count ↑↑ ↓ 
Anemia + + 
ESR ↑↑ Normal or ↓ 
CRP ↑ ↑ 
ALT/AST Normal or ↑ ↑↑ 
Fibrinogen ↑ ↓ 
Ferritin Normal or ↑ ↑↑ 
D-dimers ↑ ↑↑ 
sCD25 Normal or ↑ ↑↑ 
sCD163 Normal or ↑ ↑↑ 
Histopathological  
Features 
NK cell dysfunction Possible Frequent 
Hemophagocytic macrophages Possible Frequent 
+, often diagnosed; −/+, less commonly diagnosed/described; ↑↑, strong increase; ↑, increase; ↓, decrease. 
Abbreviations: ALT/AST, alanine aminotransferase/aspartate aminotransferase; CNS, central nervous system; 
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; NK, natural killer; sCD, soluble cluster of 
differentiation; sJIA, systemic juvenile idiopathic arthritis; MAS, macrophage activation syndrome in 
association with sJIA. 
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Both sJIA and MAS require a prompt diagnosis and management. In sJIA, therapy is started with 
nonsteroidal anti-inflammatory drugs in order to temper both joint pain and systemic features. In severe 
cases, corticosteroids are frequently prescribed, although long-term treatment with these drugs should 
be avoided to minimize side effects [42]. Traditionally, disease-modifying anti-rheumatic drugs, e.g., 
methotrexate and anti-TNF blockers, were used to minimize corticosteroid treatments. These therapeutics 
have proven their efficacy in other subtypes of JIA, but limited effectiveness was obtained in  
sJIA [43,44,68]. Since ongoing research in sJIA patients supports a disease-promoting role for IL-1β 
and IL-6 [69–72], a shift in treatment recommendations has been made towards IL-1 and IL-6 blockade. 
Both anti-IL-1β antibodies (canakinumab), IL-1 receptor antagonists (anakinra) and the anti-IL-6 
receptor antibody tocilizumab were investigated in clinical trials, with promising results [73–76]. A 
subdivision of sJIA patients into subgroups was proposed based on the specific balance of IL-6 and IL-18, 
related to clinical profile, responsiveness to therapy or sensitivity to develop MAS [77]. The IL-6-dominant 
group presented mainly with arthritic symptoms, while the IL-18-dominant group seemed prone to 
develop MAS [78,79]. The subdivision based on the response to anakinra, as proposed by Gattorno and 
colleagues [80], can also be explained by an IL-1β/IL-18 dominant subgroup and an IL-6-dominant 
group [59,76]. The use of cytokine-related therapy is complex, as cytokine expression may arise in 
phases of disease and patients’ responses may alter during the disease course. In addition to cytokine-related 
therapy, other used therapeutics are cyclosporine A and thalidomide, both with moderate effectiveness 
and important side effects. Finally, autologous stem cell transplantation is considered in patients who 
have failed anti-IL-1 and anti-IL-6 treatment [42,43,81,82]. The importance of ongoing research into the 
pathogenesis of sJIA and the need for new treatment options are highlighted by the fact that a group of 
sJIA patients still fails to respond to recommended therapies or escapes after initial response [83]. 
3.2. IFN-γ in sJIA: Lessons from a New Mouse Model 
The strong macrophage-activating potential of IFN-γ led to the consideration of the cytokine as  
proinflammatory agent in both sJIA and MAS. Indeed, IFN-γ levels are vastly increased in HLH  
patients [84–88], and murine models of the inherited form of HLH point to IFN-γ as the dominant 
causative cytokine [89,90]. In sJIA, the exact role of IFN-γ is subject of discussion. Despite the high 
inflammatory status of the patients, only moderately augmented IFN-γ levels have been detected in 
plasma. This observation is in sharp contrast with the highly elevated levels of IL-18, a signature  
IFN-γ-inducing cytokine [80,84]. Furthermore, de Jager and colleagues reported a defective IFN-γ 
production by NK cells of sJIA patients upon stimulation with IL-18 [91] and microarray analysis 
demonstrated an absence of IFN-γ -induced gene expression in peripheral blood mononuclear cells 
(PBMCs) from active sJIA patients [84,92,93]. When stimulating PBMCs of sJIA patients in vitro with 
IFN-γ, a normal response was noted [84,94]. All these data point to a limited exposure to IFN-γ in vivo 
in sJIA, arguing against a pivotal disease-enforcing role. 
We recently described a new mouse model of systemic inflammation in IFN-γ-deficient BALB/c 
mice [20], in which symptoms correspond well to the characteristics of sJIA. The model relied on a 
single subcutaneous injection of complete Freund’s adjuvant (CFA), the most commonly used 
immunoadjuvant for the induction of experimental autoimmune diseases. CFA consists of a viscous 
emulsion of paraffin oil mixed with aqueous solutions or suspensions of antigens, and heat-killed 
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mycobacteria (Mycobacterium tuberculosis or others). When antigens are emulsified in this oily 
adjuvant, their in vivo life span is prolonged resulting in an enhanced immune response. However, even 
in the absence of autoantigen both innate and adaptive immune reactions are provoked by CFA. The 
killed mycobacterial component acts as a booster for the immune response by eliciting extensive 
myelopoiesis and by skewing the immune response towards Th1 and γδ T cells [95–97]. The CFA-induced 
inflammation occurs in the first place at the site of injection and in the draining lymph nodes, where the 
hyperplasia, architectural changes and granuloma formation resemble a primary infection with living 
mycobacteria. Systemically, CFA acts through TLR activation, induction of cytokine and chemokine 
production and enhancement of antigen uptake by antigen-presenting cells. Hematopoietic remodeling 
takes place in the spleen, with disruption of the normal splenic architecture, leukocyte proliferation and 
granuloma formation [96]. In WT BALB/c mice, CFA challenge only results in a subtle and transient 
inflammatory reaction. IFN-γ-deficient mice however present with massive splenomegaly, 
lymphadenopathy, increased cytokine expression, anemia, thrombocytosis, granulocytosis, an immature 
blood cell profile and deficient NK cell cytotoxicity, all of which correspond to sJIA symptoms. Injection 
of CFA-treated WT mice with neutralizing antibodies against IFN-γ results in a comparable syndrome, 
indicating that a transient deficiency in IFN-γ suffices to induce sJIA-like symptoms (our own 
unpublished observations). Replacement of CFA by incomplete Freund’s adjuvant (IFA, not containing 
mycobacteria particles) has only subtle effects on the immune system [20], suggesting that the 
mycobacterial components in CFA account for the powerful immune reaction to the adjuvant, 
particularly in the absence of IFN-γ. As was mentioned earlier, IFN-γ (receptor)-deficient mice are 
extremely susceptible to infection with mycobacteria [98,99]. Therefore, the protective nature of IFN-γ 
in this context may result from the use of CFA and the consequent involvement of mycobacterium 
particles. However, the remarkable low levels of IFN-γ in sJIA patients, despite high IL-18 levels, are 
indicative of a protective function for the cytokine in the disease as well. 
3.3. Comparison with CFA-Induced Experimental Autoimmune Diseases 
In contrast to autoinflammatory disorders, autoimmune diseases, such as RA and MS, are 
characterized by immune reactions against self-antigens. IFN-γ-producing Th1 cells were historically 
heralded as signature pathogenic players in the onset and progress of these diseases. However, in 
associated experimental models, endogenous IFN-γ was found to fulfill a more subtle role, either 
augmenting or suppressing autoimmunity in a context-specific manner [7,100–102]. Evidence for the 
regulatory capacities of IFN-γ came from observations in CIA and EAE [7]. Like the sJIA-like model, 
those models rely on the use of CFA in the induction procedure. In both CIA and EAE, an aggravation 
of disease symptoms was noted in mice deficient in IFN-γ or its receptor [100–102]. It is now clear that 
both disease models are Th17-mediated, and that the protective effect of IFN-γ is most likely explained 
by its suppressive capacity on the differentiation and effector functions of the Th17 cells [22,103,104]. 
This assumption has been supported by the finding that ablation of IL-17, the major product of Th17 cells, 
counteracts the disease symptoms in mice with deficient IFN-γ pathways [105–107]. Of note, disease 
attenuation by IFN-γ in CIA and EAE is probably also mediated by other protective mechanisms, like 
suppression of neutrophil infiltration and tissue-destructive enzyme production, inhibition of 
osteoclastogenesis (CIA) and induction of Treg cell development [7,10]. 
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It is an oversimplification to conclude that IFN-γ completely annihilates inflammation in RA and MS, 
as evident from results obtained in the corresponding CFA-induced mouse model. In CFA-independent 
models for RA, IFN-γ acts to enhance the inflammatory processes [98,108,109]. It is now commonly 
accepted that endogenous IFN-γ can exert both a disease-promoting and disease-mitigating role, 
depending on collateral conditions and on the time frame wherein the disease progresses [7,10,110]. 
Likewise, Th1 cells are not simply protective cell types in the diseases. A good understanding of the role 
of Th1 cells and IFN-γ in a specific autoimmune disease is advisable before considering therapeutic 
usage of antagonists of endogenous IFN-γ or of recombinant IFN-γ itself. 
3.4. Comparison with Mouse Models of MAS 
To compare the CFA-induced sJIA model with models independent of CFA, we highlight a mouse 
model covering the growth retardation seen in sJIA and two models with MAS-like features.  
Chronic inflammation or recurrent infections in children have a vast effect on the normal growth rate, 
particularly during periods of augmented disease activity [111]. Stunted growth is a major complication 
of sJIA; the excessive production of IL-6 is one of the factors held responsible. The relation between 
high levels of IL-6 and reduced growth rates was demonstrated by De Benedetti et al. in neurospecific 
enolase (NSE)/hIL-6 mice, which have excessive expression of human IL-6 cDNA in mature neuron 
and neuroendocrine cells driven by the rat NSE promoter [112]. Growth defects were noted in some of 
the generated transgenic lines, with adult mice 50%–70% the size of WT littermates. Analysis of these 
lines demonstrated high circulating levels of IL-6, due to leaky expression in organs other than the 
central nervous system. Blockade of IL-6 restored the growth rate, indicating that the defects were a 
direct consequence of increased IL-6. Although no symptoms of arthritis were reported, the model could 
be of great help to increase our understanding of the aspect of growth retardation in sJIA and other 
chronic childhood disorders characterized by growth retardation [112,113]. Strippoli et al. developed a 
mouse model of MAS by administration of different TLR ligands to these IL-6 transgene mouse lines 
that displayed stunted growth [114]. LPS injection in the transgene mice resulted in increased lethality 
and elevated serum levels of IL-1β, IL-6, IL-18 and TNF-α compared to WT mice. Ferritin and sCD25 
were increased, whereas platelet and neutrophil counts, and hemoglobin levels were significantly 
decreased. In vitro pretreatment of human macrophages with IL-6 likewise resulted in increased 
expression of cytokines when stimulated with LPS, indicating that exposure to high IL-6 levels affects 
the activation status of macrophages. This model provides insight into the development of MAS in sJIA. 
High IL-6 levels are a common feature of sJIA patients, which may partially explain the predisposition 
of sJIA patients to develop MAS after an infection. Concerning the role of IFN-γ in this model, it was 
recently described that treatment with antibodies against IFN-γ resulted in increased survival of the mice, 
assigning a proinflammatory role to the cytokine in this experimental system (abstract at the European 
Pediatric Rheumatology (PReS) Congress 2014) [115]. 
A second mouse model of MAS relies on chronic stimulation of TLR9 [116]. WT mice were given a 
series of intraperitoneal injections with CpG every two days for 10 days, resulting in pancytopenia, 
anemia, thrombocytopenia, splenomegaly, hepatitis, and hyperferritinemia. Serum levels of IL-12p70, 
IL-6, IL-10 and IFN-γ were elevated. TNF-α levels were not increased and blockade of the cytokine did 
not result in amelioration of the symptoms. Symptoms remained unchanged when only depleting NK 
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cells or CD8+ cells, while mice lacking all lymphocyte populations showed attenuation of most of the 
disease parameters with exception of hepatitis. In IFN-γ-deficient mice, anemia, thrombocytopenia and 
hepatitis were absent, and splenomegaly was reduced, suggesting a proinflammatory role for IFN-γ. 
Leukopenia and hyperferritinemia were IFN-γ-independent. Hemophagocytosis, an important MAS 
symptom, was only observed after blocking IL-10, pointing to a protective function of IL-10 in the 
syndrome. In general, disruption of IL-10 resulted in a more severe disease, indicated by the authors as 
“fulminant MAS” [117]. Mice deficient in IFN-γ in which IL-10 was ablated developed essentially the 
same symptoms as WT mice when experiencing fulminant MAS, with exception of anemia. This model 
system indicates that MAS can be initiated by a hyperactive innate immune response. The MAS-like 
syndrome consists of a spectrum of disease severity depending on the levels of the protective IL-10. In 
the more severe disease conditions, i.e., fulminant MAS, IFN-γ is not the causative agent, although 
increased levels were seen. Hemophagocytosis is associated with more severe disease, and may be part 
of a non-specific response to severe systemic inflammation, independent from the action of IFN-γ, but 
inhibited by IL-10. 
Of note, both MAS models depend on the use of TLR triggers. The mouse model of Strippoli  et al. 
indicates that chronic IL-6 exposure leads to an excessive amplification of immune responses after a 
single injection of TLR ligands [114]. In the CpG-induced model, MAS-like symptoms are provoked by 
repeated activation of TLRs [116]. 
3.5. Hypothesis 
To summarize, the exact role of IFN-γ in sJIA remains complex. As for other experimental systems 
relying on CFA in the induction procedure, the CFA-induced sJIA-like syndrome indicates a protective 
role for IFN-γ in the disease. This regulatory function was not observed in MAS models, implying that 
IFN-γ may have a different role in sJIA versus MAS. However, a direct proinflammatory role of IFN-γ 
was also questioned in the CpG-dependent “fulminant MAS” model. 
In the sJIA model, we hypothesize that the anti-inflammatory features of IFN-γ are needed to appease 
chronic inflammation elicited by CFA, by inhibiting IL-17-producing cells and stimulating NK cell 
cytotoxicity and cytokine production (Figure 2, left and middle). In humans, an unknown trigger in 
genetically predisposed children starts a cascade of reactions with excessive production of proinflammatory 
cytokines, predominantly IL-6 and IL-18 (Figure 2, right). These cytokines may impair adequate 
functioning of NK cells. Indeed, it was recently demonstrated that high levels of IL-6 are associated with 
decreased NK cell function [118]. As a consequence, NK cells are unable to kill activated immune cells 
and terminate the immune response. Also, they fail to produce sufficient amounts of IFN-γ, which under 
normal circumstance may help to end inflammatory processes, e.g., via inhibition of IL-17-producing 
Th17 cells and through induction of IL-18 binding protein. Thus, in our opinion, the cause of the 
symptoms in the mouse model and humans may differ, but inadequate termination of the immune 
response eventually leads to similar symptoms, typically encountered in sJIA. IFN-γ may be essential to 
cooperate in an appropriate termination of inflammation under certain circumstances. 
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Figure 2. Proposed disease mechanism in mice and patients, with a central protective role 
of IFN-γ. (Left) In mice, complete Freund’s adjuvant (CFA) injection results in a local and 
systemic inflammatory reaction, leading to the expression of proinflammatory cytokines by 
activated immune cells. In wild-type mice (middle), IFN-γ counteracts the production of 
these cytokines by inhibiting IL-17-producing cells and by inducing NK cell cytotoxicity. 
Triggered NK cells kill activated immune cells by the release of cytotoxic granules. In the 
absence of IFN-γ (IFN-γ-deficient mice, left), NK cell function is defective, and activated 
immune cells keep producing proinflammatory cytokines. IFN-γ-associated inhibition of IL-17 
is absent. As a consequence, the immune response is not ended properly, eventually resulting 
in typical sJIA-like symptoms; (right) In patients, an unknown trigger and genetic 
predisposition result in an excessive immune response, with high levels of proinflammatory 
cytokines, such as IL-6 and IL-18. These cytokines inhibit a proper NK cell functionality. 
As a consequence, less IFN-γ is produced and activated cells cannot be killed, resulting in 
the typical sJIA-like symptoms. Dashed arrows indicate impaired pathways. 
4. Therapeutic Potential of IFN-γ in Autoinflammatory Disorders 
The pleiotropic effects of IFN-γ and its immunomodulatory functions imply a great therapeutic 
potential. The first clinical trials with recombinant human IFN-γ were conducted in 1986, defining its 
pharmacokinetics and side effects [119]. In more recently performed clinical trials, recombinant IFN-γ 
(actimmune or IFN-γ1b) and adenovirus vectors expressing IFN-γ cDNA have been used for treatment 
of a variety of disorders, including cancer, tuberculosis, hepatitis, osteopetrosis and scleroderma [119]. 
For the treatment of autoimmune diseases, both the use of recombinant IFN-γ and antibodies against 
IFN-γ (e.g., fontolizumab) have been considered, perfectly illustrating the dual role of the cytokine in 
these disorders [120–124]. 
In the inherited forms of HLH, a pathogenic role was assigned to IFN-γ based on different animal 
models [89,90], which has led to clinical trials with a new neutralizing antibody NI-0501. A first trial, 
investigating the safety of this new antibody in healthy volunteers, has been completed 
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(ClinicalTrials.gov Identifier: NCT01459562). Clinicians are now recruiting patients with the inherited 
form of HLH for monitoring the safety and efficacy of NI-0501 and for long-term follow-up of patients 
treated with the drug (ClinicalTrials.gov Identifier: NCT01818492 and NCT02069899). 
In sJIA, IFN-γ -related therapy is not under consideration at this time. Our results in mice certainly 
demonstrate that care should be taken with neutralization of IFN-γ, as they are suggestive of a protective 
role of the cytokine in the disease. In line with these assumptions, two research groups independently 
demonstrated effective treatment of sJIA with recombinant IFN-γ [125,126]. Mild side effects were 
observed, but the authors suggested a treatment strategy which involved exogenous IFN-γ in those sJIA 
patients that resisted to other treatments. Off course, the line between sJIA and MAS seems very thin, 
and either too little or too much IFN-γ could have devastating consequences. Therefore, a task that lies 
ahead for researchers is to deepen insights into the regulatory effects of IFN-γ in the diseases. 
5. Concluding Remarks 
While the role of IFN-γ in for example tuberculosis is clearly established, the exact contribution of 
the cytokine as proinflammatory or protective agent in autoinflammation remains a subject of dispute. 
The cytokine is involved in both pro- and anti-inflammatory circuits, thereby acting as a two-edged 
sword. Its proinflammatory properties, like macrophage activation and induction of Th1 polarization, 
serve the purpose of inducing a strong immune inflammatory reaction. On the other hand, important 
anti-inflammatory functions, including inhibition of T cell proliferation and induction of apoptosis, help 
to limit an excessive immune response in chronic inflammation. It may be important to note that many 
features of endogenous IFN-γ in immune processes have been established in mice in which IFN-γ was 
knocked out or neutralized by specific antibodies, and by using experimentally induced models of 
inflammation. Therefore some of the activities of IFN-γ may be related to the use of non-primates or 
may be conditioned by induction procedures (such as CFA). A better understanding of the biological 
activities of IFN-γ in human inflammatory disorders like sJIA and MAS is required, especially if the 
aim is to use this cytokine (or its antagonist) in medical practice. A detailed analysis of the disease, the 
patient and other treatment options may thus be necessary prior to considering IFN-γ-related therapy. 
Indeed, the administration of IFN-γ in an artificial way may result in side effects when dose or location 
do not correspond to the complex in vivo situation. A similar danger concerns anti-IFN-γ therapy, as 
blockade of the protective activities of the cytokine may have a great impact on chronic inflammation. 
The therapeutic window to use IFN-γ or its antagonists in autoinflammation may be narrow, depending 
on a combination of many factors. 
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